文献速递神经肿瘤

伽玛刀立体定向放射外科治疗海绵窦脑膜瘤:200例患者长期随访

Gamma Knife stereotactic radiosurgery for cavernous sinus meningioma: long-term follow-up in 200 patients.
PubMed 文献 · J Neurosurg · 2018-07-20

该研究回顾性评估200例海绵窦脑膜瘤患者接受立体定向放射外科(SRS)后5-18年的结局,中位影像随访101个月。5年、10年、15年肿瘤控制率分别为92%、84%、75%;显微手术后肿瘤进展史是不利反应的独立预测因素(p=0.009,HR=4.161,95%CI 1.438-12.045)。

要点

  • 5年、10年、15年肿瘤控制率分别为92%、84%、75%。
  • 显微手术后肿瘤进展史是不利反应的独立预测因素(p=0.009,HR=4.161,95%CI 1.438-12.045)。
  • 肿瘤体积较大(≥10 cm3)患者更易发生永久性颅神经并发症(p=0.046,HR=3.629,95%CI 1.026-12.838)。

核心结论

  • 伽玛刀放射外科为大多数海绵窦脑膜瘤患者提供了长期肿瘤控制。
  • 因显微手术后进展性肿瘤而接受SRS的患者,肿瘤生长的可能性大于无手术史或显微手术后残留肿瘤接受治疗的患者。

研究设计与样本

  • 回顾性评估200例海绵窦脑膜瘤患者接受SRS后5-18年的治疗结局。
  • 患者中位年龄57岁(范围22-83岁)。
  • 120例(60%)以伽玛刀SRS作为主要治疗,46例(23%)治疗残留肿瘤,34例(17%)治疗一次或多次手术后的复发肿瘤。
  • 中位肿瘤靶体积7.5 cm3(范围0.1-37.3 cm3),中位边缘剂量13.0 Gy(范围10-20 Gy)。

主要发现

  • 中位影像随访101个月期间,121例(61%)肿瘤体积缩小,49例(25%)不变,30例(15%)增大。
  • 5年、10年、15年 actuarial 肿瘤控制率分别为92%、84%、75%。
  • 120例以SRS作为主要治疗(primary SRS)的患者中,14例(11.7%)在中位48.9个月(范围4.8-120.0个月)观察到肿瘤进展,SRS后1年、5年、10年、15年 actuarial 肿瘤控制率分别为98%、93%、85%、85%。
  • 显微手术后肿瘤进展史是不利反应的独立预测因素(p=0.009,HR=4.161,95%CI 1.438-12.045)。
  • 170例至少有一种颅神经(CN)缺损的患者中,44例(26%)在SRS后改善;初始显微外科切除后新发CN缺损是SRS后改善的不利因素(p=0.014,HR=0.169,95%CI 0.041-0.702)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The authors of this study evaluate the long-term outcomes of stereotactic radiosurgery (SRS) for cavernous sinus meningioma (CSM). METHODS: The authors retrospectively assessed treatment outcomes 5-18 years after SRS in 200 patients with CSM. The median patient age was 57 years (range 22-83 years). In total, 120 (60%) patients underwent Gamma Knife SRS as primary management, 46 (23%) for residual tumors, and 34 (17%) for recurrent tumors after one or more surgical procedures. The median tumor target volume was 7.5 cm3 (range 0.1-37.3 cm3), and the median margin dose was 13.0 Gy (range 10-20 Gy). RESULTS: Tumor volume regressed in 121 (61%) patients, was unchanged in 49 (25%), and increased over time in 30 (15%) during a median imaging follow-up of 101 months. Actuarial tumor control rates at the 5-, 10-, and 15-year follow-ups were 92%, 84%, and 75%, respectively. Of the 120 patients who had undergone SRS as a primary treatment (primary SRS), tumor progression was observed in 14 (11.7%) patients at a median of 48.9 months (range 4.8-120.0 months) after SRS, and actuarial tumor control rates were 98%, 93%, 85%, and 85% at the 1-, 5-, 10-, and 15-year follow-ups post-SRS. A history of tumor progression after microsurgery was an independent predictor of an unfavorable response to radiosurgery (p = 0.009, HR = 4.161, 95% CI 1.438-12.045). Forty-four (26%) of 170 patients who had presented with at least one cranial nerve (CN) deficit improved after SRS. Development of new CN deficits after initial microsurgical resection was an unfavorable factor for improvement after SRS (p = 0.014, HR = 0.169, 95% CI 0.041-0.702). Fifteen (7.5%) patients experienced permanent CN deficits without evidence of tumor progression at a median onset of 9 months (range 2.3-85 months) after SRS. Patients with larger tumor volumes (≥ 10 cm3) were more likely to develop permanent CN complications (p = 0.046, HR = 3.629, 95% CI 1.026-12.838). Three patients (1.5%) developed delayed pituitary dysfunction after SRS. CONCLUSIONS: This long-term study showed that Gamma Knife radiosurgery provided long-term tumor control for most patients with CSM. Patients who underwent SRS for progressive tumors after prior microsurgery had a greater chance of tumor growth than the patients without prior surgery or those with residual tumor treated after microsurgery.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Park KJ, Kano H, Iyer A, et al. Gamma Knife stereotactic radiosurgery for cavernous sinus meningioma: long-term follow-up in 200 patients. J Neurosurg. 2018. PMID: 30028261. doi:10.3171/2018.2.JNS172361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。